Moderna’s 177% Surge: The Short Squeeze That Exposed Wall Street’s Vaccine Blind Spot
Moderna shares soared 177% in three days after Phase 3 data for its personalized melanoma vaccine mRNA-4157 (V940) met key endpoints, triggering a $5.5 billion...
Enter code for secure login, or use password.
请选择您喜欢的登录方式
